This phase I-II study aimed to determine the maximum tolerated dose (MTD) of paclitaxel (Taxol), infused over 3 hours, when combined with a fixed dose (90 mg/m²) of epirubicin. Other aims were to investigate the combination’s
Ilaria Pazzagli, MD
Advertisement
Articles by Ilaria Pazzagli, MD
Advertisement
Latest Updated Articles
- Paclitaxel Plus Epirubicin in Advanced Breast Cancer
Published: January 1st 1998 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
2
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
3
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
4
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
5
